Meet “Molecule” – the Pharma Development Disruptor
Open source platforms have transformed software development and led to lower costs for consumers. What would happen if pharmaceutical R&D applied a similar approach?
Paul Kohlhaas | | Longer Read
Blockchain technology in the pharma industry is commonly associated with supply chain management, but the technology can be used in other ways to benefit drug developers. At my not-for-profit company, Molecule, we have developed a platform using blockchain technology to create a more collaborative approach for drug development. I like to describe Molecule as a platform that offers an open market for intellectual property, where researchers, companies or investors can acquire shares in a molecule and/or work on the molecule to contribute to its development.
Read the full article now
Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE!
Login
Or register now - it’s free!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine
